



### Company Overview

Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from MD Anderson and recently cleared by the FDA. The Company's first commercial product uses rapid pulses of designed acoustic shockwaves to dramatically accelerate the removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in bringing Rapid Acoustic Pulse ("RAP") device to the market. The Company believes this "Soliton" method cannot only dramatically accelerate tattoo removal, but also has the potential to lower removal cost for patients, while increasing profitability to practitioners, and to reduce the potential for unwanted side effects from current laser removal methods. Soliton has discovered other capabilities of the RAP technology during preclinical testing, including the potential to assist existing fat reduction technology in the reduction of fat as well as reducing the appearance of cellulite by creating mechanical stress at the cellular level and inducing significant collagen growth.

### Soliton to Present Poster on Pivotal Cellulite Data at Virtual American Society for Dermatologic Surgery (ASDS) 2020 Annual Meeting

Oct 5 2020, 8:01 AM EDT

### Soliton Selects Lippe Taylor Group as its Public Relations and Customer Engagement Agency

Sep 29 2020, 8:01 AM EDT

### Management Team

#### Walter V. Klemp

Co-Founder and Executive Chairman

#### Christopher Capelli, M.D.

Co-Founder, President and Chief Science Officer

#### Lori Bisson

Chief Financial Officer

#### Joe Tanner

Chief Operating Officer

#### Mary Stoll

Senior Director of Clinical Development

#### Robert "Joe" Mills

Vice President of Supply Chain

#### James Bucher

Senior Sales Consultant

### Soliton, Inc.

5304 Ashbrook Dr.  
Houston, TX 77081

### Investor Relations

The Ruth Group  
Jan Medina, CFA  
T: 646-536-7035  
[jmedina@theruthgroup.com](mailto:jmedina@theruthgroup.com)

### Stock Overview

Symbol	SOLY
Exchange	Nasdaq
Market Cap	182.87m
Last Price	\$8.63
52-Week	\$5.69 - \$15.50

10/20/2020 04:00 PM EDT

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and

uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.